- Important data for a CAR T technology that highlights its potential for patients with late-stage diffuse large B-cell lymphoma;
- A new therapeutic approach to help address anemia associated with myelofibrosis, myelodysplastic syndromes and beta-thalassemia; and
- Late-stage data in a maintenance setting for patients with newly diagnosed acute myeloid leukemia, where a significant unmet need still exists.
In addition to this clinical data, we will also share early research, further underscoring the promise of our broad discovery pipeline.
And, recognizing that patients’ needs go beyond the medicines to treat cancer, we are proud to showcase research that seeks to understand the real-world outcomes associated with certain cardiovascular conditions among patients with cancer. With this objective in mind, we have also recently shared data on a novel way to potentially help prevent graft-versus-host disease in patients with blood cancer who received a stem cell transplant, resulting in a Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
We look forward to ASH not only for the opportunities to share data from our combined pipeline and portfolio but importantly, for the opportunities to connect with the broader cancer community, including researchers, advocates and other partners. We dedicate our time with this community to build relationships and further the dialogue around our shared goals of advancing treatments for patients living with cancer.
The research we will present at ASH represent years of dedication and passion focused on improving treatment options for patients. I am very proud of the strong presence we will have at this important conference and the outstanding work of our teams. As I think about what these and other research advances could potentially mean for patients I am incredibly excited about the future and what’s to come.
Chairman and Chief Executive Officer
Bristol Myers Squibb